ラタノプロストの中国市場

China Research and Intelligenceが発行した調査報告書(DATA8102334)
◆英語タイトル:Investigation Report on Chinese Latanoprost Market, 2018-2022
◆商品コード:DATA8102334
◆発行会社(リサーチ会社):China Research and Intelligence
◆発行日:2018年7月
◆ページ数:30
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,200 ⇒換算¥237,600見積依頼/購入/質問フォーム
EnterprisewideUSD3,300 ⇒換算¥356,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はChina Research and Intelligence社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DescriptionAccording to WHO’s data in 2005, glaucoma is the second leading cause of blindness after cataracts and the most common irreversible cause of blindness in the world. There are 70 million glaucoma patients worldwide, and it is estimated that the number will reach 80 million in 2020. Blindness caused by glaucoma accounts for 50% of global blindness. China has the largest number (over 24 million) of glaucoma patients in the world, and this number is growing at a rate of more than 1.5 million per year.
Latanoprost is the first FDA approved prostaglandin for intraocular pressure reduction. In 1999, China began importing Latanoprost as a first-line drug in the clinical treatment of glaucoma. In 2004, Latanoprost eye drops developed by Lunan Better were approved for sale, followed by the products of other domestic manufacturers. And there is a continuous rise in the market share of domestic manufacturers. In 2017, Pfizer had the largest market share by sales value, about 39%, a figure that has been declining in recent years.
According to CRI, Latanoprost has been growing since it entered China, with its sales value exceeding CNY 40 million in 2017. With an ageing population, the incidence of glaucoma is increasing year by year in China. In clinical practice, glaucoma cannot be well treated through operations as cataracts. Therefore, there is a promising market of conservative medications and post-operative medications, and thus a high demand for Latanoprost in China.

Topics Covered:
- Development environment of Latanoprost in China
- Sales of Latanoprost in China
- Major Latanoprost manufacturers in China
- Retail prices of Latanoprost in China
- Prospects of Chinese Latanoprost market

【レポートの目次】

Table of Contents
1 Basic Concepts of Latanoprost
1.1 Indications for Latanoprost
1.2 Development History of Latanoprost in China
1.3 Governmental Approval of Latanoprost in China

2 Investigation on Sales of Latanoprost in China, 2013-2017
2.1 Sales Value of Latanoprost in China
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Value of Latanoprost in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Parts of China
2.3 Sales of Latanoprost in China by Dosage Form

3 Major Latanoprost Manufacturers in China
3.1 Market Competition of Latanoprost in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer’s Latanoprost in China
3.3 Pharmacia
3.3.1 Enterprise Profile
3.3.2 Sales of Pharmacia’s Latanoprost in China
3.4 Lunan Better Pharmaceutical Co., Ltd.
3.5 China Resources Zizhu Pharmaceutical Co., Ltd.
3.6 Taejoon Pharm
3.7 Chengdu Hengrui Pharmaceutical Co., Ltd.

4 Analysis on Prices of Latanoprost in China, 2017-2018
4.1 Prices of Latanoprost in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers’ Latanoprost in China
4.2.1 Pfizer (Xalatan)
4.2.2 Pharmacia (Xalatan)
4.2.3 Lunan Better Pharmaceutical Co., Ltd. (Telijie)
4.2.4 China Resources Zizhu Pharmaceutical Co., Ltd. (Jiankang)
4.2.5 Taejoon Pharm (Ruidaxi)
4.2.6 Chengdu Hengrui Pharmaceutical Co., Ltd. (Shengao)

5 Prospects of Chinese Latanoprost Market, 2018-2022
5.1 Factors Influencing Latanoprost Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Competition Pattern

Selected Charts
Chart Governmental Approval of Latanoprost in China
Chart Sales Value of Latanoprost in China, 2013-2017
Chart Sales Value of Latanoprost in Parts of China, 2013-2017
Chart Sales Volume of Latanoprost in China, 2013-2017
Chart Sales Volume of Latanoprost in Parts of China, 2013-2017
Chart Market Share and Sales Value of Pfizer’s Latanoprost in China, 2013-2017
Chart Market Share and Sales Value of Pharmacia’s Latanoprost in China, 2013-2017
Chart Market Share and Sales Value of Lunan Better Pharmaceutical Co., Ltd.’s Latanoprost in China, 2013-2017
Chart Prices of Pfizer’s Latanoprost in Several Chinese Cities, 2017-2018
Chart Prices of Pharmacia’s Latanoprost in Several Chinese Cities, 2017-2018
Chart Prices of Lunan Better Pharmaceutical Co., Ltd.’s Latanoprost in Several Chinese Cities, 2017-2018
Chart Forecast on Sales Value of Latanoprost in China, 2018-2012



【レポートのキーワード】

ラタノプロスト

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ラタノプロストの中国市場(Investigation Report on Chinese Latanoprost Market, 2018-2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆